Tuberculosis

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made in consultation with a qualified healthcare provider, considering the individual patient's circumstances, the latest evidence, and local guidelines. This content is based on current medical knowledge and guidelines but is subject to change as new evidence emerges.

Overview

• Definition: Tuberculosis (TB) is a chronic infectious disease primarily caused by Mycobacterium tuberculosis. It most commonly affects the lungs (pulmonary TB) but can affect any other organ (extrapulmonary TB). The infection can be latent (asymptomatic, non-transmissible) or active (symptomatic, potentially transmissible).
• Epidemiology:
  • Global Burden: TB remains one of the top infectious killers worldwide. The World Health Organization (WHO) estimates that 10 million people fell ill with TB in 2022 and 1.3 million died from it.
  • Geographic Distribution: The majority of cases occur in low- and middle-income countries, with the highest burden in the WHO regions of South-East Asia and Africa. India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh, and the Democratic Republic of Congo account for a significant proportion of global cases.
  • Demographics: TB affects all age groups. Individuals living with HIV are at a significantly higher risk of developing active TB and severe outcomes. Other vulnerable populations include contacts of TB patients, healthcare workers, people with substance use disorders, prisoners, migrants, and immunocompromised individuals.
  • Drug Resistance: Multidrug-resistant TB (MDR-TB, resistant to at least isoniazid and rifampicin) and extensively drug-resistant TB (XDR-TB, resistant to isoniazid, rifampicin, any fluoroquinolone, and at least one of the Group A second-line injectables) pose significant global health threats.
• Classification:
  • Latent Tuberculosis Infection (LTBI): Presence of M. tuberculosis in the body without active disease. Individuals are asymptomatic and non-contagious but have a risk (5-10% lifetime risk, much higher in immunocompromised) of progressing to active TB.
  • Active Tuberculosis Disease:
    • Pulmonary TB: Affects the lung parenchyma. This is the most common and often contagious form.
    • Extrapulmonary TB (EPTB): Affects organs outside the lungs. Common sites include pleura, lymph nodes, bone/joints, genitourinary tract, abdomen, meninges, and pericardium. EPTB is generally not considered contagious, except in specific cases (e.g., laryngeal TB, cavitary pulmonary TB with associated endobronchial spread).
    • Miliary TB: Disseminated TB disease with widespread hematogenous dissemination, affecting multiple organs simultaneously. Often seen in immunocompromised individuals.

Pathophysiology

• Mechanism:
  1. Inhalation: M. tuberculosis bacilli are aerosolized in respiratory droplets from an individual with active pulmonary TB and inhaled by a susceptible host.
  2. Alveolar Macrophage Uptake: Bacilli reach the alveoli, where they are engulfed by alveolar macrophages. Unlike most bacteria, M. tuberculosis can survive and replicate within macrophages, evading lysosomal killing.
  3. Primary Infection/Granuloma Formation: Macrophages present mycobacterial antigens, triggering a cell-mediated immune response (Type IV hypersensitivity reaction). T-lymphocytes (CD4+ and CD8+) activate macrophages to contain the infection, forming a granuloma (a localized collection of immune cells, primarily macrophages, lymphocytes, and fibroblasts).
  4. Latent Infection: In most immunocompetent individuals (90-95%), the immune system successfully contains the bacilli within granulomas, leading to LTBI. The bacilli remain viable but dormant.
  5. Reactivation/Active Disease: If the host's immune system weakens (e.g., due to HIV, immunosuppression, aging, malnutrition), the granulomas can break down, allowing the bacilli to multiply and disseminate, leading to active TB disease. This can be primary progression (soon after initial infection) or reactivation (years later).
  6. Tissue Damage: Active replication of bacilli causes inflammation and tissue necrosis, often leading to caseation (cheese-like necrosis) and cavitation in the lungs, which facilitates further transmission through expelled aerosols.
• Risk Factors:
  • Immunosuppression: HIV infection (strongest risk factor, 20-30x increased risk), organ transplantation, long-term corticosteroid use, TNF-alpha inhibitors (e.g., for rheumatoid arthritis, Crohn's disease), silicosis, diabetes mellitus, chronic kidney disease/dialysis, malignancy (especially head/neck cancer, hematologic malignancies).
  • Close Contact: Prolonged, close contact with an individual with active, smear-positive pulmonary TB.
  • Geographic Origin: Birth or travel to high TB prevalence areas.
  • Socioeconomic Factors: Poverty, homelessness, overcrowding, incarceration, substance abuse (alcoholism, IV drug use).
  • Malnutrition: Undernutrition weakens the immune system.
  • Prior TB: Inadequately treated or recurrent TB.
  • Age Extremes: Very young children (under 5 years) and elderly individuals.
• Protective Factors:
  • Intact Cell-Mediated Immunity: A robust immune system is the primary defense against M. tuberculosis.
  • BCG Vaccination: Provides some protection against severe forms of TB (e.g., TB meningitis, disseminated TB) in children, though variable efficacy against adult pulmonary TB.
  • Improved Living Conditions: Reducing overcrowding and improving ventilation.
  • Prompt Diagnosis and Treatment: Effective treatment of active cases prevents transmission.
  • Latent TB Treatment: Preventing progression to active disease in high-risk individuals.

Clinical Presentation

Signs and Symptoms

• Cardinal Features (Pulmonary TB): Often insidious onset, can be non-specific.
  • Chronic Cough: Persistent cough (>2-3 weeks), initially dry, progressing to productive with mucopurulent sputum, sometimes hemoptysis.
  • Fever: Low-grade, often evening fevers, typically resolving in the morning.
  • Night Sweats: Drenching sweats requiring changing clothes/bedding, particularly at night.
  • Weight Loss/Anorexia: Unexplained, progressive weight loss and loss of appetite.
  • Fatigue/Malaise: General feeling of unwellness.
• Early Signs: Often non-specific or mild, easily mistaken for common respiratory infections:
  • Mild cough
  • Low energy
  • Anorexia
• Advanced Signs: Indicate more extensive disease or complications:
  • Hemoptysis: Coughing up blood (ranging from blood-streaked sputum to frank blood).
  • Dyspnea: Shortness of breath, especially with exertion.
  • Chest Pain: Pleuritic chest pain (sharp, worsens with breathing) if pleura involved.
  • Cachexia: Severe muscle wasting and emaciation.
  • Hoarseness: If laryngeal TB is present.
• Atypical Presentations: More common in immunocompromised individuals, elderly, or children.
  • Extrapulmonary TB: Symptoms depend on the affected organ:
    • Lymph Node TB (Scrofula): Painless, chronic enlargement of cervical or supraclavicular lymph nodes, may form draining sinuses.
    • Pleural TB: Pleuritic chest pain, dyspnea, fever.
    • Skeletal TB (Pott's Disease): Back pain, deformity (kyphosis), neurological deficits (if spinal cord compressed).
    • Genitourinary TB: Sterile pyuria, hematuria, flank pain, dysuria, abdominal pain.
    • TB Meningitis: Gradual onset headache, fever, neck stiffness, altered mental status, cranial nerve palsies. (Medical emergency!)
    • Pericardial TB: Chest pain, dyspnea, signs of heart failure (e.g., peripheral edema, JVD). May lead to constrictive pericarditis.
    • Abdominal TB: Abdominal pain, weight loss, fever, ascites, bowel obstruction.
  • Miliary TB: Often presents with non-specific constitutional symptoms (fever, weight loss, malaise) but can progress to respiratory failure, organ dysfunction.

Physical Examination

• Inspection:
  • General: Cachexia, pallor, signs of chronic illness.
  • Respiratory: Evidence of dyspnea, use of accessory muscles, asymmetrical chest expansion.
  • Lymph Nodes: Enlarged, non-tender, firm lymph nodes (cervical, supraclavicular, axillary), possibly matted or with draining sinuses (scrofula).
  • Skin: Erythema nodosum (less common), lupus vulgaris (cutaneous TB).
  • Spine: Kyphosis or gibbus deformity (Pott's disease).
• Palpation:
  • Lymph Nodes: Palpable adenopathy as above.
  • Tactile Fremitus: May be increased over areas of consolidation or decreased over effusions.
  • Tenderness: Over affected bones/joints in skeletal TB.
• Percussion:
  • Dullness: Over areas of consolidation or pleural effusion.
• Auscultation:
  • Lungs: Adventitious breath sounds such as crackles (rales), rhonchi, bronchial breath sounds over consolidated areas. Diminished breath sounds over effusions.
  • Heart: Pericardial friction rub or muffled heart sounds in pericardial TB.
• Special Tests:
  • Neurological Exam: Crucial for suspected TB meningitis (meningeal signs like nuchal rigidity, Kernig's/Brudzinski's sign, cranial nerve palsies, altered mental status).
  • Joint Examination: For suspected TB arthritis (swelling, tenderness, decreased range of motion).

Diagnostic Approach

History Taking

• Key Questions:
  • Symptoms: Onset, duration, character of cough, sputum production (color, amount, presence of blood), fever pattern, night sweats, weight loss, fatigue.
  • Exposure: Known contact with an active TB patient (household, work, social setting), particularly within the last 2 years.
  • Risk Factors: HIV status, history of immunosuppressive conditions or medications (e.g., corticosteroids, TNF-alpha inhibitors), diabetes, chronic kidney disease, silicosis, history of substance abuse.
  • Geographic History: Birth in or prolonged residence/travel to high TB burden countries.
  • Prior TB: History of past TB disease (diagnosis, treatment regimen, completion, outcome) or latent TB infection (diagnosis, treatment).
  • BCG Vaccination: History of BCG vaccination (important for TST interpretation).
  • Occupational History: Healthcare worker, correctional facility worker, homeless shelter resident.
  • Social History: Housing, socioeconomic status, recent incarceration.
• Red Flags:
  • Persistent cough (>2-3 weeks) with any of the classic constitutional symptoms (fever, night sweats, weight loss).
  • Hemoptysis.
  • Any unexplained fever of unknown origin in a high-risk individual.
  • Unexplained lymphadenopathy, especially cervical.
  • Neurological symptoms (headache, confusion, focal deficits, neck stiffness) in a patient with risk factors for TB.
  • Progressive weight loss and decline in functional status without other clear cause.
  • HIV infection with any respiratory or constitutional symptoms.

Laboratory Tests

• First-Line (for Active TB Suspicion):
  • Sputum Acid-Fast Bacilli (AFB) Smear Microscopy: Rapid, inexpensive. Requires collection of 3 sputum samples (at least one early morning sample preferred). Sensitivity varies (50-70%), higher in cavitary disease. Confirms presence of AFB, but cannot differentiate M. tuberculosis from non-tuberculous mycobacteria.
  • Nucleic Acid Amplification Tests (NAATs):
    • Xpert MTB/RIF (GeneXpert): Endorsed by WHO. Detects M. tuberculosis DNA and rifampicin resistance mutations simultaneously within 2 hours. High sensitivity (90-98% for smear-positive, 70% for smear-negative pulmonary TB) and specificity. Can be performed on sputum, CSF, lymph node aspirate, and other body fluids.
    • Other NAATs: e.g., Truenat, Loop-mediated isothermal amplification (LAMP) – becoming more widely available.
  • Tuberculosis Skin Test (TST) / Interferon-Gamma Release Assays (IGRAs):
    • Purpose: Primarily for diagnosis of LTBI or as an adjunct in active TB diagnosis (positive in 70-80% of active cases). They do not differentiate between LTBI and active disease.
    • TST (Mantoux test): 0.1 mL of 5 TU PPD tuberculin injected intradermally. Read 48-72 hours later. Induration (not erythema) diameter measured. Interpretation varies by risk group:
      • ≥5 mm: HIV-positive, recent contacts, fibrotic changes on CXR, organ transplant recipients, immunosuppressed.
      • ≥10 mm: Recent immigrants from high-prevalence countries, IV drug users, residents/employees of high-risk settings (prisons, nursing homes), mycobacteriology lab personnel, children <4 years, people with certain medical conditions (diabetes, ESRD, silicosis).
      • ≥15 mm: Persons with no known risk factors.
      • BCG vaccination can cause a false positive TST, but a strongly positive TST (e.g., >10-15mm) in a BCG-vaccinated individual living in a high-burden setting should still raise suspicion.
    • IGRAs (e.g., QuantiFERON-TB Gold Plus, T-SPOT.TB): Measure IFN-γ release by T-cells in response to specific M. tuberculosis antigens (ESAT-6, CFP-10). Less affected by BCG vaccination than TST. Preferred for individuals who received BCG, or who may not return for TST reading.
• Confirmatory (for Active TB):
  • Mycobacterial Culture: Gold standard for TB diagnosis. Allows for species identification and crucial drug susceptibility testing (DST). Takes 2-6 weeks for liquid culture, longer for solid media. Essential for guiding treatment, especially in areas with drug resistance.
    • Specimens: Sputum (most common), bronchoalveolar lavage (BAL), gastric aspirates (children), urine, CSF, biopsy specimens (lymph node, pleura, lung, bone, etc.), pus, blood (in miliary/disseminated TB, especially in HIV-positive individuals).
  • Drug Susceptibility Testing (DST): Performed on initial positive cultures. Phenotypic DST involves growing the bacteria in the presence of anti-TB drugs. Genotypic DST (molecular assays) detects resistance-associated mutations (e.g., rpoB for rifampicin, katG/inhA for isoniazid).
• Monitoring:
  • Sputum Smear and Culture: Monthly during initial treatment phase to assess response and determine sputum conversion (typically negative by month 2).
  • Liver Function Tests (LFTs): Baseline and monthly (or more frequently if symptoms arise) due to hepatotoxicity risk of INH, RIF, PZA. Monitor AST, ALT, bilirubin.
  • Complete Blood Count (CBC): Baseline and periodically.
  • Renal Function Tests: Baseline (creatinine, BUN).
  • Uric Acid: Baseline and periodically if pyrazinamide is used (can cause hyperuricemia).
  • Ophthalmologic Exam: Baseline and monthly if ethambutol is used (monitor for optic neuritis).
  • Audiometry: Baseline and periodically if aminoglycosides (e.g., streptomycin, amikacin, kanamycin) are used for DR-TB.

Imaging

• Recommended:
  • Chest X-ray (CXR): Primary imaging modality for pulmonary TB. Findings suggestive of active pulmonary TB:
    • Upper lobe infiltrates: Often in apical or posterior segments.
    • Cavitation: Air-filled spaces within consolidation, highly suggestive of active, transmissible TB.
    • Nodules: Single or multiple.
    • Hilar or mediastinal lymphadenopathy: Especially in primary TB or in children/immunocompromised.
    • Pleural effusion: Unilateral, exudative.
    • Miliary pattern: Diffuse, fine, uniformly distributed small nodules (1-3 mm) throughout both lung fields, suggestive of hematogenous dissemination.
    • Fibrotic changes, calcifications, volume loss: Suggestive of old, healed TB or chronic disease.
• Advanced:
  • Computed Tomography (CT) Scan of the Chest: Provides more detailed anatomical information, especially useful for:
    • Confirming lesions not clearly seen on CXR.
    • Evaluating extent of disease (e.g., endobronchial spread, adenopathy).
    • Detecting subtle cavitation.
    • Differentiating active from inactive disease.
    • Guiding biopsies.
  • MRI/CT of other sites: For suspected extrapulmonary TB (e.g., brain for TB meningitis, spine for Pott's disease, abdomen for abdominal TB, lymph node imaging).
  • Ultrasound: Can be used for evaluation of abdominal TB (e.g., ascites, lymphadenopathy) or superficial lymph nodes.

Management

Acute Management

• Immediate:
  • Respiratory Isolation: For all suspected or confirmed pulmonary TB patients, especially those with positive sputum smears or cavitary disease. Place in an airborne infection isolation room (AIIR) or single room with door closed. Use N95 or higher respirators for healthcare workers upon entry.
  • Initiate Empiric Anti-TB Therapy: As soon as TB is strongly suspected, especially in high-burden settings or in patients with severe disease, before culture results are available. Empiric regimen should be standard first-line drugs unless drug resistance is highly suspected based on patient history (e.g., previous treatment failure, contact with DR-TB).
  • Sputum Collection: Obtain at least 2-3 sputum samples for AFB smear, NAAT, and culture/DST.
• Stabilization:
  • Fluid and Nutritional Support: Many patients are malnourished and dehydrated.
  • Symptomatic Management: Antipyretics for fever, analgesics for pain.
  • Oxygen Therapy: If hypoxemic.
  • Management of Hemoptysis: If severe, may require airway protection, tranexamic acid, or rarely embolization/surgery.
  • Addressing Comorbidities: Especially HIV, diabetes, and other immunosuppressive conditions.
• Emergency:
  • Respiratory Distress/Failure: May require intubation and mechanical ventilation. Rule out pneumothorax or massive pleural effusion.
  • Massive Hemoptysis: Defined as >100-600 mL in 24 hours. A medical emergency requiring airway protection, identifying source (bronchoscopy), and potentially bronchial artery embolization or surgical resection.
  • TB Meningitis: Rapid diagnosis and immediate initiation of TB drugs (including corticosteroids for adjunctive therapy) is critical to prevent neurological sequelae and death.
  • Cardiac Tamponade (Pericardial TB): Requires urgent pericardiocentesis.

Chronic Management

• Pharmacological:
  • Principles: Multi-drug regimens are essential to prevent the emergence of drug resistance and to achieve cure. Directly Observed Therapy (DOT) is strongly recommended, especially in the intensive phase, to ensure adherence.
  • Standard First-Line Regimen (Drug-Susceptible Pulmonary TB):
    • Intensive Phase (Initial): 2 months of daily Rifampin (R), Isoniazid (H), Pyrazinamide (Z), and Ethambutol (E) (RIPE).
      • Dosing (adults, daily):
        • Isoniazid (H): 5 mg/kg (max 300 mg)
        • Rifampin (R): 10 mg/kg (max 600 mg)
        • Pyrazinamide (Z): 25 mg/kg (max 2000 mg)
        • Ethambutol (E): 15-20 mg/kg (max 1200 mg)
      • Fixed-dose combinations (FDCs) are preferred to improve adherence.
    • Continuation Phase: 4 months of daily Rifampin (R) and Isoniazid (H).
      • Dosing (adults, daily):
        • Isoniazid (H): 5 mg/kg (max 300 mg)
        • Rifampin (R): 10 mg/kg (max 600 mg)
    • Total Duration: 6 months (2 months RIPE + 4 months RH).
    • Exceptions/Modifications:
      • TB Meningitis/Bone/Joint TB: Often require longer treatment (9-12 months). Corticosteroids (e.g., Dexamethasone) are often added for TB meningitis.
      • HIV Co-infection: Standard 6-month regimen usually adequate for drug-susceptible TB, but ART initiation should be carefully timed (usually 2-8 weeks into TB treatment) to prevent IRIS.
      • Culture-negative TB: Treated similarly but diagnosis requires strong clinical suspicion and radiographic evidence.
  • Regimens for Latent TB Infection (LTBI):
    • Isoniazid (H) daily for 6 or 9 months.
    • Isoniazid (H) + Rifapentine (RPT) weekly for 3 months (DOT recommended).
    • Rifampin (R) daily for 4 months.
  • Drug-Resistant TB (DR-TB): Requires specialized regimens guided by DST results and WHO/national guidelines. These regimens are longer (6-24 months), more complex, use second-line drugs (fluoroquinolones, bedaquiline, pretomanid, delamanid, clofazimine, linezolid, injectable agents like amikacin/capreomycin), and often have more severe side effects.
• Non-pharmacological:
  • Directly Observed Therapy (DOT): A cornerstone of TB management. A healthcare worker or trained community member observes the patient taking every dose of medication. Crucial for ensuring adherence, especially for multi-drug regimens and long treatment durations.
  • Nutritional Support: Adequate nutrition is vital for recovery and immune function. Dietary counseling, and sometimes nutritional supplements, are important.
  • Psychosocial Support: Addressing mental health issues, stigma, and social determinants of health to improve treatment adherence and outcomes.
  • Infection Control: Continue respiratory isolation until sputum smears are negative (typically 3 consecutive negative smears collected 8-24 hours apart, after clinical improvement).
• Monitoring:
  • Clinical Monitoring: Daily/weekly assessment for symptoms (fever, cough, weight changes), adverse drug reactions, and adherence.
  • Microbiological Monitoring: Sputum smear and culture monitoring during treatment:
    • Smear: Monthly until negative (usually by 2 months).
    • Culture: Monthly until negative, then at the end of treatment. Conversion to negative culture is the most important indicator of treatment success.
  • Adverse Drug Reaction Monitoring:
    • Hepatotoxicity: Common with H, R, Z. Monitor LFTs. Symptoms: nausea, vomiting, dark urine, jaundice, fatigue. Hold hepatotoxic drugs if AST/ALT >5x upper limit of normal (ULN) without symptoms, or >3x ULN with symptoms.
    • Peripheral Neuropathy: With H (prevent with pyridoxine/Vitamin B6 25-50 mg daily).
    • Optic Neuritis: With E (red-green color blindness, decreased visual acuity). Baseline and monthly vision checks. Discontinue if symptoms occur.
    • Hyperuricemia/Arthralgia: With Z.
    • Flu-like Syndrome, rash, thrombocytopenia: With R.
  • Weight: Monitor weight gain as a sign of clinical improvement.
  • End of Treatment Evaluation: Final clinical assessment, CXR, and sputum cultures to confirm cure.

Treatment Algorithms

• First-Line (Drug-Susceptible TB):
  1. Diagnosis: Clinical suspicion + positive NAAT/smear + culture with DST pending.
  2. Intensive Phase (2 months): Rifampin, Isoniazid, Pyrazinamide, Ethambutol (RIPE).
     • If drug susceptibility to INH and RIF confirmed quickly, Ethambutol (E) may be stopped early.
  3. Continuation Phase (4 months): Rifampin + Isoniazid (RH).
  4. Duration: Total 6 months.
  5. Monitoring: Monthly sputum smears/cultures until conversion, LFTs, clinical assessment.
• Second-Line (Drug-Resistant TB, MDR-TB, XDR-TB):
  1. Diagnosis: Confirmed drug resistance via DST.
  2. Regimen Design: Highly individualized based on specific resistance pattern, patient history, comorbidities, and available drugs.
     • Shorter Oral Regimens (6-9 months): For select MDR-TB cases without extensive resistance (e.g., no fluoroquinolone resistance), often including bedaquiline, fluoroquinolones, linezolid, clofazimine, pyrazinamide, ethambutol.
     • Longer Regimens (18-24 months): For XDR-TB or complex MDR-TB. Includes newer drugs (bedaquiline, pretomanid, delamanid) and repurposed drugs (linezolid, clofazimine) alongside other active second-line agents.
  3. Components: Minimum of 4-5 effective drugs in the intensive phase.
  4. Monitoring: More intensive, including regular audiometry (if injectables used), ECG (bedaquiline/delamanid can prolong QT interval), electrolyte monitoring.
  5. DOT: Absolutely critical given regimen complexity and side effects.
• Refractory Cases (Treatment Failure/Recurrence):
  • Definition: Persistence of positive cultures after 4 months of treatment, or recurrence after initially completing a regimen.
  • Management:
    1. Re-evaluate Drug Resistance: Obtain new sputum samples for culture and repeat DST (both phenotypic and genotypic) to identify new or evolving resistance.
    2. Review Adherence: Crucially assess adherence to previous regimen.
    3. Review Dosing: Ensure appropriate weight-based dosing.
    4. Assess Malabsorption: Rule out conditions affecting drug absorption (e.g., HIV enteropathy).
    5. Design New Regimen: Based on new DST results, typically with at least 4-5 drugs to which the isolate is susceptible, including newer or repurposed drugs. Consultation with an expert in DR-TB is essential.
    6. Surgical Intervention: In selected cases (e.g., localized cavitary disease with persistent positive cultures despite optimal medical therapy for DR-TB), surgical resection of diseased lung tissue may be considered, but carries significant risks.

Complications

• Common:
  • Drug-induced Hepatitis: Due to INH, RIF, PZA.
  • Peripheral Neuropathy: Due to INH (prevented by pyridoxine).
  • Optic Neuritis: Due to Ethambutol.
  • Arthralgia/Gout: Due to Pyrazinamide (hyperuricemia).
  • Rash/Hypersensitivity Reactions: Can occur with any anti-TB drug.
• Serious:
  • Respiratory Failure: Due to extensive lung destruction or miliary TB.
  • Massive Hemoptysis: Life-threatening bleeding from cavitary lesions.
  • Pneumothorax/Bronchopleural Fistula: Rupture of a cavity or subpleural bleb.
  • Drug-Resistant TB: Development of MDR-TB or XDR-TB due to inadequate treatment, leading to prolonged therapy, worse outcomes, and higher mortality.
  • TB Meningitis: Severe neurological damage (hydrocephalus, stroke, vision loss, cognitive impairment) if not diagnosed and treated promptly.
  • Constrictive Pericarditis: Chronic inflammation of the pericardium, leading to impaired cardiac filling. May require pericardiectomy.
  • Addison's Disease: Adrenal insufficiency due to adrenal gland involvement.
  • Spinal Cord Compression (Pott's Disease): Neurological deficits, paralysis.
• Long-term:
  • Post-TB Lung Disease: Chronic lung damage (bronchiectasis, fibrosis, cavities, bullae) leading to persistent cough, dyspnea, and recurrent infections.
  • Sterility: In genitourinary TB.
  • Joint Deformities: In skeletal TB.
  • Renal Failure: In genitourinary TB.
  • Cognitive Impairment/Epilepsy: Sequelae of TB meningitis.
  • Psychosocial Impact: Stigma, financial burden, mental health issues (depression, anxiety).

Prognosis

• Factors Affecting Outcome:
  • Drug Susceptibility: Drug-susceptible TB has an excellent prognosis with appropriate treatment (>90% cure rate). MDR/XDR-TB have significantly lower cure rates (MDR-TB ~60%, XDR-TB ~40% globally) and higher mortality.
  • Extent of Disease: Extensive cavitary pulmonary disease, miliary TB, or TB meningitis carry a worse prognosis.
  • Immunocompromised Status: HIV co-infection, severe malnutrition, or other immunosuppressive conditions worsen prognosis.
  • Adherence to Treatment: Poor adherence is the leading cause of treatment failure, relapse, and drug resistance.
  • Timeliness of Diagnosis and Treatment: Delays can lead to more extensive disease and complications.
  • Age: Extremes of age (very young and elderly) are associated with worse outcomes.
  • Comorbidities: Diabetes, renal failure, silicosis, etc., can complicate management and outcome.
• Survival:
  • With appropriate treatment, mortality rates for drug-susceptible TB are low (<5%).
  • Mortality for MDR-TB is considerably higher (e.g., 20-40%).
  • Mortality for XDR-TB is even higher (e.g., 40-60%).
  • TB Meningitis still has a high mortality rate (up to 20-30% even with treatment), and significant neurological sequelae are common.
• Quality of Life:
  • TB can significantly impair quality of life due to chronic symptoms, long treatment duration, side effects, social stigma, and long-term lung damage.
  • Successful treatment can restore quality of life, but persistent respiratory symptoms and functional limitations are common post-TB.
  • Psychosocial support and rehabilitation are important components of holistic care.

Prevention

• Primary (Preventing Initial Occurrence):
  • Latent TB Infection (LTBI) Treatment: Treating individuals with LTBI who are at high risk of progressing to active disease.
    • Indications: Close contacts of active pulmonary TB cases, HIV-positive individuals, immunosuppressed patients (e.g., TNF-alpha inhibitor candidates, transplant recipients), recent TST/IGRA convertors.
    • Regimens:
      • Isoniazid (INH) 300 mg daily for 6 or 9 months.
      • Rifampin (RIF) 600 mg daily for 4 months.
      • Isoniazid (INH) + Rifapentine (RPT) weekly for 3 months (DOT recommended).
  • BCG Vaccination:
    • Efficacy: Varies geographically, generally good (70-80%) in preventing severe forms of TB (miliary TB, TB meningitis) in children, but limited and variable efficacy against adult pulmonary TB.
    • Indications: Recommended for infants in high-burden countries or for unvaccinated children/healthcare workers at high risk of exposure to MDR-TB. Not routinely used in low-prevalence countries.
  • Infection Control: Implementing administrative, environmental, and personal protective controls in healthcare and congregate settings.
    • Administrative: Early identification, isolation, and treatment of TB patients; training staff; risk assessments.
    • Environmental: Negative pressure isolation rooms (AIIRs), adequate ventilation, UV germicidal irradiation (UVGI).
    • Personal Protective Equipment (PPE): N95 respirators for healthcare workers entering AIIRs or when performing aerosol-generating procedures.
• Secondary (Early Detection and Intervention):
  • Contact Investigation: Systematically identifying, screening, and evaluating close contacts of active pulmonary TB cases for both active TB and LTBI. Those with LTBI are offered treatment.
  • Active Case Finding: Targeted screening programs in high-risk populations (e.g., prisoners, homeless individuals, HIV-positive individuals, migrants).
  • Prompt Diagnosis and Treatment: Rapid and accurate diagnosis of active TB and immediate initiation of effective, directly observed treatment to stop transmission and prevent progression/complications.
• Tertiary (Preventing Complications/Recurrence):
  • Adherence Support: Ensuring complete and adequate treatment through DOT and patient support programs.
  • Management of Complications: Addressing lung damage, neurological sequelae, etc., through rehabilitation and supportive care.
  • Post-treatment Follow-up: Monitoring for relapse, especially in cases of drug-resistant TB or high-risk patients.

Special Populations

• Pediatric:
  • Diagnosis Challenges: Symptoms often non-specific (failure to thrive, persistent cough), sputum collection is difficult (gastric aspirates or induced sputum may be needed). TST/IGRAs are crucial. Diagnosis often depends on contact history and CXR.
  • Clinical Presentation: Higher propensity for primary progressive disease, EPTB (lymphadenitis, meningitis), and disseminated TB (miliary TB). Cavitation is less common than in adults.
  • Treatment: Same four first-line drugs (RIPE) for 6 months, but dosages are weight-based. Pyridoxine (Vitamin B6) must be co-administered with INH in all children. Close monitoring for adverse effects.
  • LTBI Treatment: Crucial for exposed children, especially those <5 years, as they are at higher risk of progressing to active disease.
• Geriatric:
  • Atypical Presentation: Symptoms often vague (fatigue, anorexia, weight loss, generalized weakness), less likely to have cough or fever. Can mimic other age-related conditions.
  • Comorbidities: High prevalence of diabetes, chronic kidney disease, malignancy, increasing risk of TB and complicating treatment.
  • Drug Interactions: Polypharmacy increases risk of drug-drug interactions with anti-TB drugs (especially rifampin).
  • Adherence: May be challenging due to cognitive impairment, multiple medications, or social isolation.
  • Increased Drug Toxicity: Higher risk of drug-induced hepatotoxicity, neurotoxicity, and myelosuppression. Careful monitoring is essential.
• Pregnancy:
  • Diagnosis: Safe to perform CXR (with abdominal shielding), TST, IGRAs.
  • Treatment: Treatment of active TB is strongly recommended to prevent severe maternal and fetal complications.
    • First-line drugs: Isoniazid, Rifampin, Ethambutol are generally considered safe throughout pregnancy. Pyrazinamide is generally safe but often deferred until after the first trimester by some guidelines due to limited safety data in pregnancy. Streptomycin is contraindicated due to ototoxicity to the fetus.
    • Pyridoxine: Essential with INH to prevent neuropathy in mother and fetus.
    • Monitoring: Close monitoring for drug toxicity.
  • LTBI Treatment: Often deferred until after delivery, but can be considered during pregnancy if risk of progression is high.
• Comorbidities:
  • HIV Co-infection:
    • Highest Risk: Significantly increased risk of active TB, rapid progression, disseminated disease (EPTB, miliary TB), and higher mortality.
    • Clinical Presentation: Often atypical, less cavitary disease on CXR, more lymphadenopathy and EPTB.
    • Diagnosis: Lower sensitivity of TST (due to anergy), IGRAs preferred. Xpert MTB/RIF on sputum or other samples is crucial due to its rapid detection. LAM antigen test on urine can be useful for advanced HIV.
    • Treatment: Standard 6-month regimen for drug-susceptible TB is usually effective. ART should be initiated during TB treatment (typically 2-8 weeks after starting TB drugs) to reduce mortality and prevent IRIS. Careful management of drug interactions (Rifampin is a potent enzyme inducer, interacting with many ARTs).
    • Immune Reconstitution Inflammatory Syndrome (IRIS): Paradoxical worsening of TB symptoms or appearance of new TB manifestations after starting ART in HIV-TB co-infected patients. Managed symptomatically, corticosteroids may be used in severe cases (e.g., central nervous system IRIS).
  • Diabetes Mellitus: Increased risk of TB, atypical presentations, delayed sputum conversion, and higher risk of relapse. Glycemic control is important.
  • Chronic Kidney Disease/End-Stage Renal Disease (ESRD): Increased risk of TB. Dosage adjustments are needed for INH, PZA, E (dialyzable drugs, given after dialysis). RIF usually no adjustment.
  • Malignancy: Increased risk, atypical presentation, higher mortality.
  • Silicosis: High risk of TB and atypical presentation.

Clinical Pearls

• Diagnostic:
  • "Think TB": Maintain a high index of suspicion, especially in high-risk populations, or for persistent cough/constitutional symptoms, even in low-incidence settings.
  • Sputum is King: Even if CXR is suggestive, always prioritize sputum collection for smear, NAAT, and culture/DST for definitive diagnosis and resistance profiling.
  • NAAT First: Xpert MTB/RIF should be the initial diagnostic test for active TB if available, due to its speed and ability to detect rifampicin resistance.
  • Negative Smear ≠ No TB: Up to 30-50% of active pulmonary TB cases can be smear-negative. Clinical suspicion, CXR, and culture are still crucial.
  • Extrapulmonary TB: Requires invasive sampling (biopsy, fluid aspiration) for diagnosis. NAATs on EPTB samples are highly valuable.
• Treatment:
  • DOT is Non-negotiable: For active TB, DOT is the most effective strategy to ensure adherence and prevent drug resistance.
  • Adverse Effects: Educate patients on potential side effects and instruct them to report symptoms immediately. Proactive management (e.g., pyridoxine with INH) is vital.
  • Drug Interactions: Be vigilant for drug interactions, especially with rifampin (a potent CYP450 inducer) and other medications (e.g., oral contraceptives, antiretrovirals, warfarin).
  • Resistance First: Always consider drug resistance in patients with previous TB treatment, contact with DR-TB, or those failing to respond to first-line therapy.
• Pitfalls:
  • Missed Diagnosis: Due to atypical presentations, especially in immunocompromised, elderly, or children, or failure to consider TB.
  • Inadequate Sputum Samples: Not collecting enough or appropriate samples leads to delayed diagnosis.
  • Monotherapy/Incomplete Regimen: Using only one or two drugs, or stopping treatment early, is a recipe for drug resistance and treatment failure.
  • Failure to Monitor Adherence: Overestimating patient adherence without DOT.
  • Ignoring Adverse Effects: Not recognizing or managing drug toxicities, leading to patient non-adherence or serious harm.
  • Misinterpreting TST/IGRA: A positive test indicates infection, not necessarily active disease. A negative test does not rule out active disease, especially in immunocompromised individuals.
  • Neglecting Contact Tracing: Failing to identify and screen contacts allows ongoing transmission.

Recent Updates

• Guidelines:
  • WHO Consolidated Guidelines on TB (2020, 2022 updates): Emphasize shorter all-oral regimens for drug-resistant TB, inclusion of bedaquiline, pretomanid, and delamanid.
  • ATS/CDC/IDSA Guidelines (2020): Provide updated recommendations for the treatment of drug-susceptible TB disease and LTBI in the US, including shorter duration regimens for LTBI (e.g., 3HP, 4R).
  • WHO LTBI Guidelines (2020): Recommendations on systematic screening for TB disease and treatment of LTBI in high-risk groups.
• Evidence:
  • Shorter Regimens for Drug-Susceptible TB: Ongoing research into 4-month regimens for drug-sensitive pulmonary TB (e.g., utilizing higher doses of rifapentine).
  • Newer Drugs for Drug-Resistant TB: Bedaquiline, pretomanid, and delamanid have revolutionized DR-TB treatment, enabling all-oral, shorter, and more effective regimens. Clinical trials (e.g., STREAM, Nix-TB, ZeNix) have provided evidence for these new regimens.
  • Diagnostics: Increased use of non-sputum-based NAATs for extrapulmonary and pediatric TB. Urine LAM for advanced HIV-associated TB.
  • Host-Directed Therapies: Research into adjunctive therapies to boost host immunity or reduce inflammation, though not standard clinical practice yet.
• Controversies:
  • Role of BCG in Adults: Debate over the utility and efficacy of BCG vaccination in adult populations, especially in moderate-prevalence settings.
  • Optimal Duration of TB Treatment: While 6 months is standard, there's ongoing research into shortening treatment duration for drug-susceptible TB, balanced against the risk of relapse.
  • LTBI Treatment in Low-Incidence Settings: Balancing the benefits of preventing progression against the risks of drug toxicity, especially in broad screening programs.
  • Management of TB-IRIS: Optimal timing of ART initiation in HIV-TB co-infection and role of corticosteroids for paradoxical IRIS.

Key References

• Guidelines:
  • World Health Organization (WHO): Global Tuberculosis Report, Consolidated Guidelines on Tuberculosis, Guidelines for Treatment of Drug-Resistant TB, Guidelines for Latent TB Infection. (www.who.int/tb)
  • Centers for Disease Control and Prevention (CDC): Guidelines for the Treatment of Drug-Susceptible TB, Guidelines for the Treatment of Latent TB Infection, Core Curriculum on Tuberculosis. (www.cdc.gov/tb)
  • American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA)/CDC: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. (Am J Respir Crit Care Med, 2020)
• Studies:
  • REMoxTB Study (2015): Investigated a 4-month regimen containing moxifloxacin, showing non-inferiority was not met compared to standard 6-month regimen.
  • OFLOTUB Study (2017): Similar findings on short-course moxifloxacin.
  • STREAM Trial (2019): Demonstrated the effectiveness and safety of a 9-month all-oral regimen for MDR-TB.
  • Nix-TB Trial (2019) & ZeNix Trial (2022): Provided evidence for the BPaL (Bedaquiline, Pretomanid, Linezolid) regimen for XDR-TB and pre-XDR-TB, including shorter treatment duration.
• Reviews:
  • UpToDate: Comprehensive reviews on all aspects of TB.
  • Harrison's Principles of Internal Medicine: Standard textbook for infectious diseases.
  • Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: Another definitive textbook.